{
  "source": "PA-Med-Nec-Suboxone.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2059-13\nProgram Prior Authorization/Medical Necessity Buprenorphine/Naloxone Products\nMedication Suboxone® * (Brand Only)\nP&T Approval Date 7/2015, 10/2016, 3/2017, 9/2017, 9/2018, 7/2019, 7/2020, 11/2020,\n11/2021, 1/2023, 2/2024, 4/2025\nEffective Date 7/1/2025\n1. Background\nSuboxone* contains buprenorphine, a narcotic and naloxone, an opiate antagonist.\nBuprenorphine, like other opioids, has the potential for being abused. Naloxone is used to guard\nagainst misuse by blocking the effects of opiates if the drug is manipulated for injection.\nThis program requires a member to meet treatment criteria prior to the coverage of\nbuprenorphine/naloxone combination products. It also requires the member to try the preferred\ncombination product buprenorphine/naloxone (generic Suboxone) or Zubsolv prior to receiving\ncoverage for Suboxone *.\n2. Coverage Criteriaa, b:\nA. Initial Authorization\n1. Suboxone* (Brand Only) will be approved based on both of the following criteria:\na. The patient is being treated for opioid dependencec\n-AND-\nb. Both of the following:\ni. One of the following:\n(a) Submission of medical records (e.g., chart notes) documenting an inadequate\nresponse to a minimum 30-day trial of Zubsolv. (30-day trial must be completed\nprior to Prior Authorization/Medical Necessity request.)\n(b) Submission of medical records (e.g., chart notes) documenting the member has\nexperienced adverse effects or has a contraindication to Zubsolv, including the\nmanifestation of the adverse reaction or reason for contraindication\n-AND-\nii. One of the following:\n(a) Submission of medical records (e.g., chart notes) documenting an inadequate\nresponse to a minimum 30-day trial of buprenorphine/naloxone (generic\nSuboxone). (30-day trial must be completed prior to Prior Authorization/Medical\n© 2025 UnitedHealthcare Services, Inc.\n1\nNecessity request.)\n(b) Submission of medical records (e.g., chart notes) documenting the",
    " (30-day trial must be completed prior to Prior Authorization/Medical\n© 2025 UnitedHealthcare Services, Inc.\n1\nNecessity request.)\n(b) Submission of medical records (e.g., chart notes) documenting the member has\nexperienced adverse effects or has a contraindication to generic\nbuprenorphine/naloxone (generic Suboxone) including the manifestation of the\nadverse reaction or reason for contraindication\nAuthorization will be issued for 12 months.\nB. Reauthorization:\n1. Suboxone* (Brand Only) will be approved based on the following criterion:\na. Documentation of positive clinical responsec\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb Review not required for plans sitused in the state of Illinois.\nc Plans sitused in Nevada are not subject to clinical criteria. Only step therapy may be required.\n3. Additional Clinical Rules:\n• Supply limits may be in place.\n• Suboxone (Brand Only) is typically excluded from coverage. Tried/Failed criteria may be in\nplace. Please refer to plan specifics to determine exclusion status.\nNotwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Suboxone [package insert]. Richmond, VA: Indivior Inc.; December 2023.\n2. Zubsolv [package insert]. Morristown, NJ: Orexo US, Inc.; December 2023.\n3. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused\nUpdate [published correction appears in J Addict Med. 2020 May/Jun;14(3):267]. J Addict Med.\n2020;14(2S Suppl 1):1-91. doi:10.1097/ADM.0000000000000633\nProgram Prior Authorization/Medical Necessity – Buprenorphine/Naloxone\n",
    "ction appears in J Addict Med. 2020 May/Jun;14(3):267]. J Addict Med.\n2020;14(2S Suppl 1):1-91. doi:10.1097/ADM.0000000000000633\nProgram Prior Authorization/Medical Necessity – Buprenorphine/Naloxone\nProducts\nChange Control\nDate Change\n7/2015 New Program\n10/2016 Annual update. Decreased reauthorization period from 24 months to 12\nmonths. Updated references.\n3/2017 Administrative update. Removed requirement for medical record\nsubmission to verify opioid dependence diagnosis. Updated references.\n9/2017 Changed reference from intolerance to adverse reaction to Zubsolv.\n© 2025 UnitedHealthcare Services, Inc.\n2\nRemoved DEA waiver requirement.\n9/2018 Annual review. Removed reference to brand Suboxone tablets (brand\nno longer available). Updated references.\n7/2019 Removed generic Suboxone and buprenorphine/naloxone tablets from\nmedications covered by criteria. Added criteria for DATA2000\nprescriber.\n7/2020 Annual review. Updated references. Clarified timing of 30 day trial.\n11/2020 Removed criteria for DATA2000 prescriber. Removed pain\nmanagement confirmation. Updated medical records requirement.\n11/2021 Annual review. Updated references.\n1/2022 Administrative change. Illinois footnote added. Criteria retired 1/2019\nfor Illinois.\n1/2023 Updated background to include additional qualified practitioners that\nmay prescribe buprenorphine for the treatment of opioid use disorder.\nUpdated references.\n2/2024 Removed Bunavail from program, it is off the market. Added Nevada\nmandate. Updated references.\n4/2025 Annual review. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}